India, Feb. 20 -- Iovance Biotherapeutics, Inc. (IOVA), a company focused on novel polyclonal tumor infiltrating lymphocyte therapies for cancer patients, on Tuesday announced the pricing of an offering of 23,014,000 shares at $9.15 per share.
The gross proceeds from the offering, to be closed on or about February 22, are expected to be around $211 million.
Iovance intends to use the proceeds for the commercial launch of AMTAGVI, to fund ongoing clinical programs including its NSCLC registrational study, IOV-LUN-202, and its frontline advanced melanoma Phase 3 confirmatory trial, TILVANCE-301.
In addition, the proceeds will be used to continue the development of its pipeline candidates, and for other general corporate purposes.
Jefferie...